3435-23-2 Usage
Uses
Used in Pharmaceutical Industry:
5-Amino-4-phenylpyrimidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the molecular structures of potential drugs. Its presence in these compounds can contribute to the development of new therapeutic agents with anti-cancer and anti-inflammatory properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Amino-4-phenylpyrimidine is utilized as a building block in the creation of novel agrochemicals, potentially enhancing crop protection and yield through the development of new pesticides and other related products.
Used in Organic Synthesis:
5-Amino-4-phenylpyrimidine is employed as a versatile reagent in organic synthesis, allowing for the construction of a wide range of organic compounds with diverse applications across various industries.
It is crucial to handle 5-Amino-4-phenylpyrimidine with care and follow appropriate safety measures when working with it in a laboratory environment, given its chemical properties and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 3435-23-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,3 and 5 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3435-23:
(6*3)+(5*4)+(4*3)+(3*5)+(2*2)+(1*3)=72
72 % 10 = 2
So 3435-23-2 is a valid CAS Registry Number.
3435-23-2Relevant academic research and scientific papers
GSK-3 INHIBITORS
-
Page/Page column 192; 193, (2015/05/26)
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
-
Paragraph 00603, (2014/06/11)
Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
